As of 2025-05-24, the EV/EBITDA ratio of Adaptimmune Therapeutics PLC (ADAP) is -1.41. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. ADAP's latest enterprise value is 53.15 mil USD. ADAP's TTM EBITDA according to its financial statements is -37.80 mil USD. Dividing these 2 quantities gives us the above ADAP EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 10.9x - 14.5x | 13.6x |
| Forward P/E multiples | 27.0x - 34.4x | 33.8x |
| Fair Price | (4.10) - (2.17) | (3.58) |
| Upside | -1563.1% - -875.1% | -1379.6% |
| Date | EV/EBITDA |
| 2025-05-22 | -1.37 |
| 2025-05-21 | -1.37 |
| 2025-05-20 | -1.45 |
| 2025-05-19 | -1.48 |
| 2025-05-16 | -1.39 |
| 2025-05-15 | -1.31 |
| 2025-05-14 | -1.35 |
| 2025-05-13 | -1.21 |
| 2025-05-12 | -1.50 |
| 2025-05-09 | -1.49 |
| 2025-05-08 | -1.54 |
| 2025-05-07 | -1.54 |
| 2025-05-06 | -1.54 |
| 2025-05-05 | -1.55 |
| 2025-05-02 | -1.44 |
| 2025-05-01 | -1.37 |
| 2025-04-30 | -1.38 |
| 2025-04-29 | -1.30 |
| 2025-04-28 | -1.39 |
| 2025-04-25 | -1.31 |
| 2025-04-24 | -1.32 |
| 2025-04-23 | -1.28 |
| 2025-04-22 | -1.29 |
| 2025-04-21 | -1.16 |
| 2025-04-17 | -1.13 |
| 2025-04-16 | -1.15 |
| 2025-04-15 | -1.21 |
| 2025-04-14 | -1.11 |
| 2025-04-11 | -1.03 |
| 2025-04-10 | -0.98 |
| 2025-04-09 | -1.10 |
| 2025-04-08 | -1.05 |
| 2025-04-07 | -1.25 |
| 2025-04-04 | -1.26 |
| 2025-04-03 | -1.69 |
| 2025-04-02 | -1.57 |
| 2025-04-01 | -1.21 |
| 2025-03-31 | -0.87 |
| 2025-03-28 | -0.92 |
| 2025-03-27 | -1.02 |
| 2025-03-26 | -1.08 |
| 2025-03-25 | -1.21 |
| 2025-03-24 | -1.38 |
| 2025-03-21 | -1.48 |
| 2025-03-20 | -1.41 |
| 2025-03-19 | -2.50 |
| 2025-03-18 | -2.54 |
| 2025-03-17 | -2.55 |
| 2025-03-14 | -2.51 |
| 2025-03-13 | -2.50 |